The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Program in 1997, the IVI operates under a treaty signed by 40 countries and the World Health Organization. The Institute conducts research in 28 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul.
The vaccine field has been transformed by the technological advances of the past decade. Expert Review of Vaccines provides structured, informed commentary on the development and application of new vaccines and vaccine technologies. This journal aims to provide the key information needed by decision makers in the development and application of vaccines – from concept to the clinic.
Human Vaccines is a unique peer-reviewed journal that is focused exclusively on vaccines for humans. Launched in 2004, Human Vaccines provides a forum that promotes (1) interest by keeping investigators updated and (2) an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines. It is published online and in print and is accessible to a wide international audience in the academic, industrial and public sectors.
FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!
Current HIV Research aims to cover all the latest and outstanding developments of HIV research. We invite comprehensive review articles and novel and pioneering work in the basic and clinical fields on all areas of HIV research. Each issue of the journal contains a series of timely in-depth reviews and original research written by leaders in the field covering a range of current topics on HIV research. Periodically, the journal will invite guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.
BioPharm International integrates the science and business of biopharmaceutical research, development, and manufacturing. We provide practical, peer-reviewed technical solutions to enable biopharmaceutical professionals to perform effectively.
BioPharm is the longest-running peer-reviewed publication serving an international audited audience involved in the development, manufacturing of therapeutics and management of related business issues.
HPV Today is a newsletter published in English and Spanish which objective is to convey research information to clinicians and offer a comprehensive view of this rapidly evolving field. HPV Today informs on relevant advances in diagnosis, prevention and clinical management of patients as well as conveying the current thinking of the opinion leaders in the field.
If you are involved with the commercial and scientific developments of anti-infective drugs, then you should read Anti-Infective Drug News (AIN) regularly. A subscription will save you hours of time and effort tracking the latest compound/product research and commercial developments affecting the companies active in the field. Every issue of AIN provides excellent, easy-to-read and well-indexed reports.
Monitoring business developments in world anticancer drug markets is becoming more and more vital as cancer, in all its guises, remains one of the most resistant conditions. Cancer Drug News (CDN) can help you stay in touch with the companies, products, alliances and research that are shaping the global cancer market. CDN saves you the time and effort of having to track the necessary information to keep up to date with this world market. Incorporating primary resource material, augmented with data from Espicom's unique intelligence base, CDN provides a compelling, easy-to-read route to complete market knowledge.
Drug Delivery Insight (DDI) is a business news service designed to keep you in touch with the latest developments in the rapidly expanding and dynamic drug delivery market. Every comprehensive issue of Drug Delivery Insight tracks the important commercial and technology developments that are shaping the drug delivery industry and covers technologies.
Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting in- and out-licensing activities, Pharmalicensing provides partnering services, business development reports, industry news and a jobs source for candidates and employers.
Profiling with Pharmalicensing allows you access to the largest online licensing and development community, enabling you to promote your licensing opportunities, partnering needs, services and expertise. Pharmalicensing’s business development reports provide key business intelligence to biopharma dealmakers. Pharmalicensing is used by over 90,000 users per month and is a division of UTEK Corporation.
